Log in

Humanigen News Headlines (OTCMKTS:HGEN)

$0.43
-0.03 (-6.52 %)
(As of 12/8/2019 03:14 AM ET)
Today's Range
$0.42
Now: $0.43
$0.43
50-Day Range
$0.46
MA: $0.68
$0.88
52-Week Range
$0.40
Now: $0.43
$1.54
Volume5,835 shs
Average Volume6,431 shs
Market Capitalization$48.81 million
P/E RatioN/A
Dividend YieldN/A
Beta2.92

Headlines

Humanigen (OTCMKTS HGEN) News Headlines

Source:
DateHeadline
Humanigen, Inc.: Humanigen Terminates Exploration of Potential Rights OfferingHumanigen, Inc.: Humanigen Terminates Exploration of Potential Rights Offering
www.finanznachrichten.de - December 2 at 9:35 AM
Humanigen Terminates Exploration of Potential Rights OfferingHumanigen Terminates Exploration of Potential Rights Offering
finance.yahoo.com - December 2 at 9:35 AM
Humanigen to Present at the 2019 Stifel Healthcare ConferenceHumanigen to Present at the 2019 Stifel Healthcare Conference
finance.yahoo.com - November 15 at 1:29 PM
Humanigen Announces Two Abstracts Accepted at the 2019 Annual Meeting of the Society for Neuro-Oncology, including Oral Presentation on its Next Generation EphA3-CAR-THumanigen Announces Two Abstracts Accepted at the 2019 Annual Meeting of the Society for Neuro-Oncology, including Oral Presentation on its Next Generation EphA3-CAR-T
finance.yahoo.com - November 12 at 1:01 PM
Humanigen Announces Two Lenzilumab Abstracts Accepted for Presentation at 2019 Annual Meeting of American Society of HematologyHumanigen Announces Two Lenzilumab Abstracts Accepted for Presentation at 2019 Annual Meeting of American Society of Hematology
finance.yahoo.com - November 6 at 1:28 PM
Humanigen to explore potential rights offeringHumanigen to explore potential rights offering
seekingalpha.com - October 15 at 9:22 AM
Humanigen Announces Exploration of Potential Rights OfferingHumanigen Announces Exploration of Potential Rights Offering
finance.yahoo.com - October 15 at 9:22 AM
New ‘Blood Advances®’ Publication Supports Humanigen’s GM-CSF Neutralization Strategy with Lenzilumab in GvHDNew ‘Blood Advances®’ Publication Supports Humanigen’s GM-CSF Neutralization Strategy with Lenzilumab in GvHD
finance.yahoo.com - October 8 at 12:24 PM
Humanigen in-licenses technology used to prevent GvHDHumanigen in-licenses technology used to prevent GvHD
seekingalpha.com - July 22 at 6:55 PM
Humanigen Secures Exclusive Worldwide License for the Prevention of GvHD through GM-CSF Neutralization from the University of ZurichHumanigen Secures Exclusive Worldwide License for the Prevention of GvHD through GM-CSF Neutralization from the University of Zurich
finance.yahoo.com - July 22 at 9:10 AM
Humanigen Secures Exclusive Worldwide License to Gene-Editing Technology from Mayo Clinic to Improve CAR-THumanigen Secures Exclusive Worldwide License to Gene-Editing Technology from Mayo Clinic to Improve CAR-T
finance.yahoo.com - July 2 at 8:59 AM
Humanigen to Present at the Jefferies 2019 Healthcare ConferenceHumanigen to Present at the Jefferies 2019 Healthcare Conference
finance.yahoo.com - June 3 at 8:52 AM
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell LymphomaKite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
finance.yahoo.com - May 31 at 8:58 AM
Publication in blood® Highlights Potential for GM-CSF Neutralization as a Solution for CAR-T Induced NeurotoxicityPublication in blood® Highlights Potential for GM-CSF Neutralization as a Solution for CAR-T Induced Neurotoxicity
finance.yahoo.com - May 16 at 7:20 PM
Humanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual MeetingHumanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 1 at 9:04 AM
Humanigen Data Presented at the 2019 National Comprehensive Cancer Network (NCCN) Annual Conference Demonstrates Potential to Improve the Efficacy of CAR-T TherapyHumanigen Data Presented at the 2019 National Comprehensive Cancer Network (NCCN) Annual Conference Demonstrates Potential to Improve the Efficacy of CAR-T Therapy
finance.yahoo.com - March 21 at 7:06 PM
Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Accepted as Oral Presentation at the 2019 Transplantation & Cellular Therapy (TCT) Annual MeetingHumanigen Study of GM-CSF Neutralization With CAR-T Therapy Accepted as Oral Presentation at the 2019 Transplantation & Cellular Therapy (TCT) Annual Meeting
finance.yahoo.com - February 25 at 9:31 AM
Humanigen IncHumanigen Inc
www.bloomberg.com - February 21 at 9:18 AM
Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Selected for Front Cover of Current Edition of ‘blood’®, The Official Journal of the American Society of Hematology (ASH)Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Selected for Front Cover of Current Edition of ‘blood’®, The Official Journal of the American Society of Hematology (ASH)
finance.yahoo.com - February 15 at 9:07 AM
Humanigen Announces Publication Demonstrating EphA3 Receptor as an Attractive Antibody Target for Brain Cancer and Other Solid Tumor Therapy in the Journal ‘Cancers’Humanigen Announces Publication Demonstrating EphA3 Receptor as an Attractive Antibody Target for Brain Cancer and Other Solid Tumor Therapy in the Journal ‘Cancers’
finance.yahoo.com - January 4 at 10:45 AM
Lenzilumab Data Presented in Oral Presentation at the American Society of Hematology (ASH)Lenzilumab Data Presented in Oral Presentation at the American Society of Hematology (ASH)
finance.yahoo.com - December 4 at 8:56 AM
Lenzilumab Study Published in ‘blood’, the Official Journal of the American Society of Hematology (ASH), First EditionLenzilumab Study Published in ‘blood’, the Official Journal of the American Society of Hematology (ASH), First Edition
finance.yahoo.com - November 30 at 9:22 AM
Humanigen Announces Lenzilumab Study Results Accepted as Oral Presentation at the 2018 Annual Meeting of the American Society of Hematology (ASH)Humanigen Announces Lenzilumab Study Results Accepted as Oral Presentation at the 2018 Annual Meeting of the American Society of Hematology (ASH)
finance.yahoo.com - November 2 at 9:13 AM
Humanigens lenzilumab shows encouraging action in preclinical studyHumanigen's lenzilumab shows encouraging action in preclinical study
seekingalpha.com - August 20 at 4:38 PM
Humanigen Announces Positive Topline Study ResultsHumanigen Announces Positive Topline Study Results
finance.yahoo.com - August 20 at 8:55 AM
Humanigen CEO to Present at 8th Annual LD Micro InvitationalHumanigen CEO to Present at 8th Annual LD Micro Invitational
finance.yahoo.com - May 30 at 8:56 AM
Lupagen & Humanigen to explore point-of-care CAR-T therapyLupagen & Humanigen to explore point-of-care CAR-T therapy
finance.yahoo.com - May 22 at 8:47 AM
Humanigen Announces Preclinical Findings Presented on Lenzilumab’s Potential to Optimize CAR-T TherapyHumanigen Announces Preclinical Findings Presented on Lenzilumab’s Potential to Optimize CAR-T Therapy
finance.yahoo.com - May 11 at 9:27 AM
Humanigen Names Dr. Tarek Sahmoud as Chief Medical OfficerHumanigen Names Dr. Tarek Sahmoud as Chief Medical Officer
finance.yahoo.com - April 30 at 8:59 AM
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of KaloBios Pharmaceuticals, Inc. -- HGEN, formerly KBIOPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of KaloBios Pharmaceuticals, Inc. -- HGEN, formerly KBIO
finance.yahoo.com - April 19 at 8:50 AM
Humanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T SupportHumanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T Support
finance.yahoo.com - April 16 at 8:48 AM
Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic LeukemiaHumanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
finance.yahoo.com - March 15 at 8:48 AM
Humanigen Appoints Robert Savage to Board of DirectorsHumanigen Appoints Robert Savage to Board of Directors
finance.yahoo.com - March 12 at 12:05 PM
Humanigen CEO to Present at Inaugural LD Micro Virtual ConferenceHumanigen CEO to Present at Inaugural LD Micro Virtual Conference
finance.yahoo.com - March 1 at 5:23 PM
Humanigen Completes Exchange of Loan Obligations for EquityHumanigen Completes Exchange of Loan Obligations for Equity
finance.yahoo.com - February 27 at 5:28 PM
Humanigen Appoints Rainer Boehm, M.D., to Board of DirectorsHumanigen Appoints Rainer Boehm, M.D., to Board of Directors
finance.yahoo.com - February 7 at 9:40 AM
Humanigen CEO to Present at NobleCon14, BIO CEO Investor ConferencesHumanigen CEO to Present at NobleCon14, BIO CEO Investor Conferences
finance.yahoo.com - January 25 at 9:33 AM
Humanigen Signs Definitive Agreements to Exchange Loan Obligations for EquityHumanigen Signs Definitive Agreements to Exchange Loan Obligations for Equity
finance.yahoo.com - December 22 at 9:53 AM
Humanigen Announces up to $15 Million Committed Equity Financing FacilityHumanigen Announces up to $15 Million Committed Equity Financing Facility
finance.yahoo.com - November 15 at 2:53 AM
Humanigen Appoints Chief Financial OfficerHumanigen Appoints Chief Financial Officer
finance.yahoo.com - November 15 at 2:53 AM
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel